Until the mid 1990s, with the appearance of interferon beta and glatiramer 
acetate, there was no treatment for multiple sclerosis (MS). However, due to 
their moderate therapeutic potential in some patients, a broad search was 
continued to find new and more effective treatment strategies, largely 
concentrated on monoclonal antibodies (MOAB). Natalizumab, the first MOAB for 
the treatment of MS, was approved at the end of 2004, representing a major 
advance in the field of neuroimmunology. Today, there is broad experience with 
natalizumab and other MOAB (alemtuzumab, daclizumab, rituximab, ocrelizumab, 
ofatumumab and anti-lingo-1) that are pending commercialization or are under 
phase II or III of development with promising results. The present review 
analyzes the efficacy and safety results of all these drugs.